Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.93
BMY's Cash to Debt is ranked higher than
62% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. BMY: 0.93 )
BMY' s 10-Year Cash to Debt Range
Min: 0.32   Max: 2.26
Current: 0.93

0.32
2.26
Equity to Asset 0.46
BMY's Equity to Asset is ranked higher than
54% of the 728 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. BMY: 0.46 )
BMY' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.55
Current: 0.46

0.34
0.55
Interest Coverage 15.56
BMY's Interest Coverage is ranked higher than
57% of the 454 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 116.71 vs. BMY: 15.56 )
BMY' s 10-Year Interest Coverage Range
Min: 5.14   Max: 50.72
Current: 15.56

5.14
50.72
F-Score: 5
Z-Score: 5.15
M-Score: -2.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 18.90
BMY's Operating margin (%) is ranked higher than
88% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.25 vs. BMY: 18.90 )
BMY' s 10-Year Operating margin (%) Range
Min: 12.83   Max: 30.74
Current: 18.9

12.83
30.74
Net-margin (%) 15.64
BMY's Net-margin (%) is ranked higher than
89% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. BMY: 15.64 )
BMY' s 10-Year Net-margin (%) Range
Min: 8.85   Max: 56.42
Current: 15.64

8.85
56.42
ROE (%) 16.91
BMY's ROE (%) is ranked higher than
92% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.97 vs. BMY: 16.91 )
BMY' s 10-Year ROE (%) Range
Min: 14.39   Max: 71.49
Current: 16.91

14.39
71.49
ROA (%) 6.64
BMY's ROA (%) is ranked higher than
82% of the 777 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. BMY: 6.64 )
BMY' s 10-Year ROA (%) Range
Min: 5.46   Max: 34.22
Current: 6.64

5.46
34.22
ROC (Joel Greenblatt) (%) 44.94
BMY's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.60 vs. BMY: 44.94 )
BMY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 42.38   Max: 144.46
Current: 44.94

42.38
144.46
Revenue Growth (%) -4.40
BMY's Revenue Growth (%) is ranked higher than
56% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. BMY: -4.40 )
BMY' s 10-Year Revenue Growth (%) Range
Min: -5.2   Max: 10.5
Current: -4.4

-5.2
10.5
EBITDA Growth (%) -16.80
BMY's EBITDA Growth (%) is ranked higher than
55% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. BMY: -16.80 )
BMY' s 10-Year EBITDA Growth (%) Range
Min: -16.8   Max: 19.6
Current: -16.8

-16.8
19.6
EPS Growth (%) -5.10
BMY's EPS Growth (%) is ranked higher than
65% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. BMY: -5.10 )
BMY' s 10-Year EPS Growth (%) Range
Min: -22.9   Max: 30.7
Current: -5.1

-22.9
30.7
» BMY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BMY Guru Trades in Q3 2013

Paul Tudor Jones 225,000 sh (New)
Steven Cohen 1,841,982 sh (+272.1%)
Vanguard Health Care Fund 24,459,861 sh (+20.26%)
Jeremy Grantham 8,368,932 sh (+10.44%)
Ken Fisher 15,937 sh (+9.89%)
Manning & Napier Advisors, Inc 266,455 sh (+0.65%)
Dodge & Cox 80,121 sh (unchged)
Brian Rogers 5,864,800 sh (unchged)
George Soros 100,000 sh (unchged)
Jeff Auxier 5,782 sh (unchged)
Pioneer Investments 85,502 sh (-0.72%)
Murray Stahl 60,572 sh (-1.36%)
Mario Gabelli 769,900 sh (-4.32%)
Bill Frels 304,956 sh (-6.81%)
Irving Kahn 28,300 sh (-48.95%)
Jim Simons 4,338,900 sh (-49.14%)
Jean-Marie Eveillard 16,520 sh (-75.17%)
» More
Q4 2013

BMY Guru Trades in Q4 2013

Stanley Druckenmiller 954,200 sh (New)
Joel Greenblatt 11,679 sh (New)
Ken Fisher 18,138 sh (+13.81%)
Jeremy Grantham 8,939,857 sh (+6.82%)
Murray Stahl 62,672 sh (+3.47%)
Pioneer Investments 86,808 sh (+1.53%)
Brian Rogers 5,864,800 sh (unchged)
Vanguard Health Care Fund 24,459,861 sh (unchged)
Jean-Marie Eveillard 16,520 sh (unchged)
Jeff Auxier 5,782 sh (unchged)
George Soros 100,000 sh (unchged)
Dodge & Cox 79,921 sh (-0.25%)
Bill Frels 300,756 sh (-1.38%)
Irving Kahn 27,650 sh (-2.3%)
Mario Gabelli 730,771 sh (-5.08%)
Manning & Napier Advisors, Inc 241,961 sh (-9.19%)
Paul Tudor Jones 100,000 sh (-55.56%)
Steven Cohen 630,599 sh (-65.77%)
Jim Simons 41,200 sh (-99.05%)
» More
Q1 2014

BMY Guru Trades in Q1 2014

Ronald Muhlenkamp 212,015 sh (New)
Ray Dalio 4,428 sh (New)
Jim Simons 1,491,855 sh (+3521.01%)
Steven Cohen 1,821,145 sh (+188.8%)
Vanguard Health Care Fund 29,437,761 sh (+20.35%)
Irving Kahn 29,650 sh (+7.23%)
Murray Stahl 62,672 sh (unchged)
Jeff Auxier 5,782 sh (unchged)
Brian Rogers 5,864,800 sh (unchged)
Louis Moore Bacon 350,000 sh (unchged)
Jean-Marie Eveillard 16,520 sh (unchged)
Joel Greenblatt Sold Out
Stanley Druckenmiller Sold Out
George Soros Sold Out
Dodge & Cox 79,121 sh (-1%)
Bill Frels 296,839 sh (-1.3%)
Pioneer Investments 84,846 sh (-2.26%)
Mario Gabelli 686,785 sh (-6.02%)
Ken Fisher 15,733 sh (-13.26%)
Manning & Napier Advisors, Inc 206,869 sh (-14.5%)
Jeremy Grantham 4,144,419 sh (-53.64%)
Paul Tudor Jones 16,349 sh (-83.65%)
» More
Q2 2014

BMY Guru Trades in Q2 2014

Joel Greenblatt 89,363 sh (New)
Ken Fisher 49,732 sh (+216.1%)
Paul Tudor Jones 34,712 sh (+112.32%)
Jim Simons 2,459,200 sh (+64.84%)
Vanguard Health Care Fund 36,197,961 sh (+22.96%)
Brian Rogers 6,064,800 sh (+3.41%)
Pioneer Investments 85,646 sh (+0.94%)
Murray Stahl 62,972 sh (+0.48%)
Ronald Muhlenkamp 212,770 sh (+0.36%)
Steven Cohen 3,900 sh (unchged)
Ray Dalio Sold Out
Manning & Napier Advisors, Inc Sold Out
Dodge & Cox 78,921 sh (-0.25%)
Bill Frels 293,539 sh (-1.11%)
Mario Gabelli 674,685 sh (-1.76%)
Irving Kahn 27,650 sh (-6.75%)
Jean-Marie Eveillard 14,492 sh (-12.28%)
Jeff Auxier 5,043 sh (-12.78%)
Jeremy Grantham 1,821,771 sh (-56.04%)
» More
» Details

Insider Trades

Latest Guru Trades with BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-06-30 Add 22.96%0.86%$46.59 - $52.19 $ 50.653%36197961
Joel Greenblatt 2014-06-30 New Buy0.05%$46.59 - $52.19 $ 50.653%89363
Ray Dalio 2014-06-30 Sold Out $46.59 - $52.19 $ 50.653%0
Ronald Muhlenkamp 2014-03-31 New Buy1.9%$48.54 - $56.61 $ 50.65-5%212015
Vanguard Health Care Fund 2014-03-31 Add 20.35%0.73%$48.54 - $56.61 $ 50.65-5%29437761
George Soros 2014-03-31 Sold Out 0.05%$48.54 - $56.61 $ 50.65-5%0
Joel Greenblatt 2014-03-31 Sold Out 0.02%$48.54 - $56.61 $ 50.65-5%0
Ray Dalio 2014-03-31 New Buy$48.54 - $56.61 $ 50.65-5%4428
Joel Greenblatt 2013-12-31 New Buy0.02%$46.41 - $53.84 $ 50.65-1%11679
Vanguard Health Care Fund 2013-09-30 Add 20.26%0.64%$41.32 - $47.53 $ 50.6516%24459861
Jean-Marie Eveillard 2013-09-30 Reduce -75.17%0.01%$41.32 - $47.53 $ 50.6516%16520
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP830.540.24$2.00 Convertible Preferred Stock

Top Ranked Articles about Bristol-Myers Squibb Company

Vanguard Health Care Fund's Top Quarterly Holdings
Over the duration of the first quarter the Vanguard Health Care Fund purchased added three new stocks to its holdings. The fund now holds on to 86 stocks valued at $35.6 billion. The following companies are Vanguard's top portfolio holdings. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 31.40
BMY's P/E(ttm) is ranked higher than
78% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.30 vs. BMY: 31.40 )
BMY' s 10-Year P/E(ttm) Range
Min: 4.05   Max: 58.14
Current: 31.4

4.05
58.14
P/B 5.48
BMY's P/B is ranked lower than
52% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. BMY: 5.48 )
BMY' s 10-Year P/B Range
Min: 2.46   Max: 6.11
Current: 5.48

2.46
6.11
P/S 5.21
BMY's P/S is ranked higher than
52% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. BMY: 5.21 )
BMY' s 10-Year P/S Range
Min: 1.71   Max: 5.7
Current: 5.21

1.71
5.7
PFCF 23.56
BMY's PFCF is ranked higher than
88% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BMY: 23.56 )
BMY' s 10-Year PFCF Range
Min: 7.44   Max: 127.6
Current: 23.56

7.44
127.6
EV-to-EBIT 29.86
BMY's EV-to-EBIT is ranked higher than
75% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.72 vs. BMY: 29.86 )
BMY' s 10-Year EV-to-EBIT Range
Min: 6.9   Max: 179.4
Current: 29.86

6.9
179.4
Shiller P/E 19.12
BMY's Shiller P/E is ranked higher than
88% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 150.63 vs. BMY: 19.12 )
BMY' s 10-Year Shiller P/E Range
Min: 10.15   Max: 21.98
Current: 19.12

10.15
21.98
Current Ratio 1.80
BMY's Current Ratio is ranked higher than
60% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. BMY: 1.80 )
BMY' s 10-Year Current Ratio Range
Min: 1.13   Max: 2.32
Current: 1.8

1.13
2.32
Quick Ratio 1.59
BMY's Quick Ratio is ranked higher than
66% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. BMY: 1.59 )
BMY' s 10-Year Quick Ratio Range
Min: 0.93   Max: 2.07
Current: 1.59

0.93
2.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.82
BMY's Dividend Yield is ranked higher than
82% of the 458 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. BMY: 2.82 )
BMY' s 10-Year Dividend Yield Range
Min: 2.51   Max: 7.07
Current: 2.82

2.51
7.07
Dividend Payout 0.89
BMY's Dividend Payout is ranked higher than
67% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. BMY: 0.89 )
BMY' s 10-Year Dividend Payout Range
Min: 0.08   Max: 4
Current: 0.89

0.08
4
Dividend growth (3y) 3.00
BMY's Dividend growth (3y) is ranked higher than
78% of the 329 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -0.10 vs. BMY: 3.00 )
BMY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 11.4
Current: 3

0
11.4
Yield on cost (5-Year) 3.26
BMY's Yield on cost (5-Year) is ranked higher than
85% of the 466 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. BMY: 3.26 )
BMY' s 10-Year Yield on cost (5-Year) Range
Min: 2.92   Max: 8.24
Current: 3.26

2.92
8.24
Share Buyback Rate 1.30
BMY's Share Buyback Rate is ranked higher than
89% of the 561 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. BMY: 1.30 )
BMY' s 10-Year Share Buyback Rate Range
Min: 5.1   Max: -0.3
Current: 1.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.05
BMY's Price/Tangible Book is ranked higher than
56% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.53 vs. BMY: 13.05 )
BMY' s 10-Year Price/Tangible Book Range
Min: 4.5   Max: 30.41
Current: 13.05

4.5
30.41
Price/DCF (Projected) 1.67
BMY's Price/DCF (Projected) is ranked higher than
88% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.06 vs. BMY: 1.67 )
BMY' s 10-Year Price/DCF (Projected) Range
Min: 0.97   Max: 4.53
Current: 1.67

0.97
4.53
Price/Median PS Value 1.99
BMY's Price/Median PS Value is ranked higher than
57% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.26 vs. BMY: 1.99 )
BMY' s 10-Year Price/Median PS Value Range
Min: 0.74   Max: 2.71
Current: 1.99

0.74
2.71
Price/Graham Number 4.24
BMY's Price/Graham Number is ranked higher than
70% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.75 vs. BMY: 4.24 )
BMY' s 10-Year Price/Graham Number Range
Min: 1.48   Max: 6.28
Current: 4.24

1.48
6.28
Earnings Yield (Greenblatt) 3.30
BMY's Earnings Yield (Greenblatt) is ranked higher than
63% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. BMY: 3.30 )
BMY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 14.5
Current: 3.3

0.6
14.5
Forward Rate of Return (Yacktman) -13.12
BMY's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 633 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.43 vs. BMY: -13.12 )
BMY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -12.6   Max: 26.4
Current: -13.12

-12.6
26.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:BRM.Germany, BMYMP.USA
Bristol-Myers Squibb Co, a Delaware corporation was incorporated in August 1933 under the name Bristol-Myers Company. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. It is a biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in one segment: BioPharmaceuticals. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes (typically involving recombinant DNA technology), called 'biologics'. Small molecule drugs are typically administered orally, e.g., in the form of a pill or tablet, although other drug delivery mechanisms are used as well. Biologics are typically administered to patients through injections or by infusion. Its revenues come from products in the following therapeutic classes: cardiovascular; virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; immunoscience and metabolics. Regional commercial organizations are used to distribute and sell the product. The business is also supported by global corporate staff functions. These products are sold mainly to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. The Company's key prodcts include, Plavix , Avapro , Eliquis , Reyataz , Sustiva Franchise , Baraclude , Sprycel, Yervoy, Orencia among others.The Company promotes its products directly to healthcare providers such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. The Company also markets directly to consumers in the U.S. through direct-to-consumer print, radio and television and digital advertising and promotion. The markets in which the Company competes are generally broad-based and highly competitive. The Company competes with other research-based drug companies, many smaller research companies and generic drug manufacturers. The Company is subject to global regulation by regional, country, state and local agencies.
» More Articles for BMY

Headlines

Articles On GuruFocus.com
Bristol-Myers: Absolute Valuation Model versus Relative Valuation Model Aug 29 2014 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
UnitedHealth Group Up on Weak Day for the Dow Jul 17 2014 
Pharma Sector Stocks To Consider For Sustained Returns Jun 25 2014 
Johnson & Johnson (JNJ) Dividend Stock Analysis May 29 2014 
A Look at AstraZeneca’s New Drug on Diabetes May 22 2014 
Vanguard Health Care Fund's Top Quarterly Holdings Apr 30 2014 
Abbvie Inc. (ABBV) Dividend Stock Analysis Mar 21 2014 
Abbott Capturing Incremental Market Share Mar 18 2014 
Vanguard Health Care Fund’s Top Five Feb 10 2014 


More From Other Websites
Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress:... Aug 30 2014
Eli Lilly-Boehringer Drug's Cost Effectiveness Questioned Aug 29 2014
Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance Aug 28 2014
The Zacks Analyst Blog Highlights: InterMune, Kite Pharma, Amicus, Celgene and Bristol-Myers Squibb Aug 28 2014
Bristol-Myers Hepatitis C Therapy Approved in EU Aug 27 2014
[video] Facebook and Movado Downgraded, Deutsche Initiates Drugmakers Aug 27 2014
Will This Coverage Initiation Affect Bristol-Myers Squibb (BMY) Stock Today? Aug 27 2014
[$$] Bristol-Myers Hepatitis C Drug Approved in Europe Aug 27 2014
European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple... Aug 27 2014
Merck, Pfizer Combining Drugs In Lung Cancer Study Aug 26 2014
Bristol-Myers/Pfizer's Eliquis Gets Yet Another FDA Nod Aug 22 2014
Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments Aug 21 2014
5 companies that will benefit from ALS awareness Aug 21 2014
FDA clears Eliquis for new use against blood clots Aug 21 2014
FDA clears Eliquis for new use against blood clots Aug 21 2014
FDA approves use of Eliquis to treat leg, lung clots Aug 21 2014
ELIQUIS Approved for Deep Vein Thrombosis and Pulmonary Embolisms Aug 21 2014
FDA OKs use of Eliquis to treat leg, lung clots Aug 21 2014
U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary... Aug 21 2014
[$$] Bristol-Myers, Celgene to Collaborate on Cancer-Treatment Study Aug 20 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK